,paragraph,value,label,name,type,company,sent,entity,entity_type_ext,sentence,phrases,qa_temp,key,score,question,answer,GPT3 Responses
0,"The aggregate market value of the voting stock held by nonaffiliates of the registrant as of June 30, 2021, the last business day of the registrant's most recently completed second fiscal quarter, was $88,374 million. The registrant has no non voting common stock.","88,374",['Entity Public Float'],dei_EntityPublicFloat,monetaryItemType,zts,"The aggregate market value of the voting stock held by nonaffiliates of the registrant as of June 30, 2021, the last business day of the registrant's most recently completed second fiscal quarter, was $88,374 million.","$88,374 million",MONEY,"The aggregate market value of the voting stock held by nonaffiliates of the registrant as of June 30, 2021, the last business day of the registrant's most recently completed second fiscal quarter, was $88,374 million.","['aggregate market value of voting stock', 'nonaffiliates of registrant', 'last business day of completed second fiscal quarter', 'aggregate market value', 'voting stock']","['aggregate market value of voting stock', 0.9414397478103638, 'what is aggregate market value of voting stock ?', '$88,374 million']",aggregate market value of voting stock,0.9414397478103638,what is aggregate market value of voting stock ?,"$88,374 million",Voting stock held by nonaffiliates
1,"The number of shares outstanding of the registrant's common stock as of February 11, 2022 was 471,970,580 shares.","471,970,580","['Entity Common Stock, Shares Outstanding']",dei_EntityCommonStockSharesOutstanding,sharesItemType,zts,"The number of shares outstanding of the registrant's common stock as of February 11, 2022 was 471,970,580 shares.","471,970,580",CARDINAL,"The number of shares outstanding of the registrant's common stock as of February 11, 2022 was 471,970,580 shares.","['number of outstanding shares', 'number', 'outstanding shares', 'common stock']","['outstanding shares', 0.8466656804084778, 'how many outstanding shares ?', '471,970,580']",outstanding shares,0.8466656804084778,how many outstanding shares ?,"471,970,580",Number of shares outstanding
2,"Accounts receivable, less allowance for doubtful accounts of $17 in 2021 and $20 in 2020",17,['Allowance for doubtful accounts'],us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent,monetaryItemType,zts,"Accounts receivable, less allowance for doubtful accounts of  $17  in 2021 and $20 in 2020",$17,MONEY,"Accounts receivable, less allowance for doubtful accounts of  $17  in 2021 and $20 in 2020","['less allowance for doubtful accounts', 'doubtful accounts', 'less allowance', 'doubtful accounts']","['less allowance for doubtful accounts', 0.2971174418926239, 'What is $17 ?', 'less allowance for doubtful accounts']",less allowance for doubtful accounts,0.2971174418926239,What is $17 ?,less allowance for doubtful accounts,2021 accounts receivable less allowance for doubtful accounts
3,"Accounts receivable, less allowance for doubtful accounts of $17 in 2021 and $20 in 2020",20,['Allowance for doubtful accounts'],us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent,monetaryItemType,zts,"Accounts receivable, less allowance for doubtful accounts of  $17  in 2021 and $20 in 2020",$20,MONEY,"Accounts receivable, less allowance for doubtful accounts of  $17  in 2021 and $20 in 2020","['less allowance for doubtful accounts', 'doubtful accounts', 'less allowance', 'doubtful accounts']","['', 0, '', '']",,0.0,,,"Accounts receivable, less allowance for doubtful accounts"
4,"Property, plant and equipment, less accumulated depreciation of $2,072 in 2021 and $1,952 in 2020","2,072",['Accumulated depreciation'],us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,monetaryItemType,zts,"Property, plant and equipment, less accumulated depreciation of $2,072 in 2021 and $1,952 in 2020","$2,072",MONEY,"Property, plant and equipment, less accumulated depreciation of $2,072 in 2021 and $1,952 in 2020","['accumulated depreciation', 'accumulated depreciation']","['Property, plant and equipment', 0.5068967342376709, 'What is $2,072 ?', 'Property, plant and equipment']","Property, plant and equipment",0.5068967342376709,"What is $2,072 ?","Property, plant and equipment","property, plant, and equipment accumulated depreciation"
5,"Property, plant and equipment, less accumulated depreciation of $2,072 in 2021 and $1,952 in 2020","1,952",['Accumulated depreciation'],us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment,monetaryItemType,zts,"Property, plant and equipment, less accumulated depreciation of $2,072 in 2021 and $1,952 in 2020","$1,952",MONEY,"Property, plant and equipment, less accumulated depreciation of $2,072 in 2021 and $1,952 in 2020","['accumulated depreciation', 'accumulated depreciation']","['Property, plant and equipment', 0.16990651190280914, 'What is $1,952 ?', 'Property, plant and equipment']","Property, plant and equipment",0.1699065119028091,"What is $1,952 ?","Property, plant and equipment","Accumulated depreciation of property, plant, and equipment"
6,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","6,000,000,000","['Common stock, shares authorized']",us-gaap_CommonStockSharesAuthorized,sharesItemType,zts,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","6,000,000,000",CARDINAL,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively",['Common stock at December'],"['Common stock', 0.2821199297904968, 'What is 6,000,000,000 ?', 'Common stock']",Common stock,0.2821199297904968,"What is 6,000,000,000 ?",Common stock,Authorized shares
7,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","501,891,243","['Common stock, shares outstanding', 'Common stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,zts,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","501,891,243",CARDINAL,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively",['Common stock at December'],"['shares issued', 0.966620683670044, 'What is 501,891,243 ?', 'shares issued']",shares issued,0.966620683670044,"What is 501,891,243 ?",shares issued,Common stock shares issued
8,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","501,891,243","['Common stock, shares outstanding', 'Common stock, shares issued']",us-gaap_CommonStockSharesIssued,sharesItemType,zts,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","501,891,243",CARDINAL,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively",['Common stock at December'],"['shares issued', 0.966620683670044, 'What is 501,891,243 ?', 'shares issued']",shares issued,0.966620683670044,"What is 501,891,243 ?",shares issued,Common stock shares issued
9,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","472,574,090","['Common stock, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,zts,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","472,574,090",CARDINAL,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively",['Common stock at December'],"['Common stock', 0.4991509020328522, 'What is 472,574,090 ?', 'Common stock']",Common stock,0.4991509020328522,"What is 472,574,090 ?",Common stock,"shares outstanding at December 31, 2021"
10,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","475,317,751","['Common stock, shares outstanding']",us-gaap_CommonStockSharesOutstanding,sharesItemType,zts,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively","475,317,751",CARDINAL,"Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued; 472,574,090 and 475,317,751 shares outstanding at December 31, 2021 and 2020, respectively",['Common stock at December'],"['shares outstanding', 0.6401739120483398, 'What is 475,317,751 ?', 'shares outstanding']",shares outstanding,0.6401739120483398,"What is 475,317,751 ?",shares outstanding,"shares outstanding at December 31, 2020"
11,"Treasury stock, at cost, 29,317,153 and 26,573,492 shares of common stock at December 31, 2021 and 2020, respectively","29,317,153",['Treasury shares'],us-gaap_TreasuryStockShares,sharesItemType,zts,"Treasury stock, at cost, 29,317,153 and 26,573,492 shares of common stock at December 31, 2021 and 2020, respectively","29,317,153",CARDINAL,"Treasury stock, at cost, 29,317,153 and 26,573,492 shares of common stock at December 31, 2021 and 2020, respectively","['Treasury stock at cost', 'shares of common stock', 'common stock']","['Treasury stock at cost', 0.6488450169563293, 'how many Treasury stock at cost ?', '29,317,153']",Treasury stock at cost,0.6488450169563293,how many Treasury stock at cost ?,"29,317,153","Treasury stock, at cost"
12,"Treasury stock, at cost, 29,317,153 and 26,573,492 shares of common stock at December 31, 2021 and 2020, respectively","26,573,492",['Treasury shares'],us-gaap_TreasuryStockShares,sharesItemType,zts,"Treasury stock, at cost, 29,317,153 and 26,573,492 shares of common stock at December 31, 2021 and 2020, respectively","26,573,492",CARDINAL,"Treasury stock, at cost, 29,317,153 and 26,573,492 shares of common stock at December 31, 2021 and 2020, respectively","['Treasury stock at cost', 'shares of common stock', 'common stock']","['shares of common stock', 0.8990911245346069, 'how many shares of common stock ?', '26,573,492']",shares of common stock,0.8990911245346069,how many shares of common stock ?,"26,573,492","Treasury stock, at cost"
13,"(a) As of December 31, 2021 and 2020, includes $3 million and $2 million, respectively, of restricted cash.",3,['Restricted cash'],us-gaap_RestrictedCashCurrent,monetaryItemType,zts,"(a)    As of December 31, 2021 and 2020, includes $3 million and $2 million, respectively, of restricted cash.",$3 million and $2 million,MONEY,"    As of December 31, 2021 and 2020, includes $3 million and $2 million, respectively, of restricted cash.",['restricted cash'],"['restricted cash', 0.8878965377807617, 'What is $3 million and $2 million ?', 'restricted cash']",restricted cash,0.8878965377807617,What is $3 million and $2 million ?,restricted cash,Restricted cash
14,"(a) As of December 31, 2021 and 2020, includes $3 million and $2 million, respectively, of restricted cash.",2,['Restricted cash'],us-gaap_RestrictedCashCurrent,monetaryItemType,zts,"(a)    As of December 31, 2021 and 2020, includes $3 million and $2 million, respectively, of restricted cash.",$3 million and $2 million,MONEY,"    As of December 31, 2021 and 2020, includes $3 million and $2 million, respectively, of restricted cash.",['restricted cash'],"['restricted cash', 0.8878965377807617, 'What is $3 million and $2 million ?', 'restricted cash']",restricted cash,0.8878965377807617,What is $3 million and $2 million ?,restricted cash,of restricted cash
15,"Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health technology. We organize and operate our business in two geographic regions: the United States (U.S.) and International.",two,['Number of regional segments'],zts_NumberofRegionalSegments,integerItemType,zts,We organize and operate our business in two geographic regions: the United States (U.S.) and International.,two,CARDINAL,We organize and operate our business in two geographic regions: the United States  and International.,['geographic regions'],"['geographic regions', 0.8572921752929688, 'how many geographic regions ?', 'two']",geographic regions,0.8572921752929688,how many geographic regions ?,two,geographic regions
16,"We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, marketing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: vaccines, parasiticides, anti infectives, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics.",45,['Number of countries in which entity markets products'],us-gaap_NumberOfCountriesInWhichEntityOperates,integerItemType,zts,"We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America.",45,CARDINAL,"We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America.",['countries across North America'],"['countries across North America', 0.803013801574707, 'how many countries across North America ?', '45']",countries across North America,0.803013801574707,how many countries across North America ?,45,"North America, Europe, Africa, Asia, Australia and South America"
17,"We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, marketing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: vaccines, parasiticides, anti infectives, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics.",100,['Number of countries in which entity markets products'],us-gaap_NumberOfCountriesInWhichEntityOperates,integerItemType,zts,"Our products are sold in more than 100 countries, including developed markets and emerging markets.",more than 100,CARDINAL,"Our products are sold in more than 100 countries, including developed markets and emerging markets.",[],"['products', 0.43086469173431396, 'What is more than 100 ?', 'products']",products,0.4308646917343139,What is more than 100 ?,products,developed markets and emerging markets
18,"We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, marketing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: vaccines, parasiticides, anti infectives, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics.",eight,['Number of core animal species'],zts_NumberOfCoreAnimalSpeciesMarketed,integerItemType,zts,"We have a diversified business, marketing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: vaccines, parasiticides, anti infectives, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics.",eight,CARDINAL,"We have a diversified business, marketing products across eight core species: dogs, cats and horses  and cattle, swine, poultry, fish and sheep ; and within seven major product categories: vaccines, parasiticides, anti infectives, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics.","['marketing products across core species', 'diversified business', 'core species', 'major product categories']","['marketing products across core species', 0.9153369665145874, 'how many marketing products across core species ?', 'eight']",marketing products across core species,0.9153369665145874,how many marketing products across core species ?,eight,"core species

Entity: 
seven
Phrase:
major product categories"
19,"We directly market our products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. Our products are sold in more than 100 countries, including developed markets and emerging markets. We have a diversified business, marketing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: vaccines, parasiticides, anti infectives, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics.",seven,['Number of major product categories'],zts_NumberOfMajorProductCategories,integerItemType,zts,"We have a diversified business, marketing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within seven major product categories: vaccines, parasiticides, anti infectives, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics.",seven,CARDINAL,"We have a diversified business, marketing products across eight core species: dogs, cats and horses  and cattle, swine, poultry, fish and sheep ; and within seven major product categories: vaccines, parasiticides, anti infectives, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics.","['marketing products across core species', 'diversified business', 'core species', 'major product categories']","['major product categories', 0.9043933153152466, 'how many major product categories ?', 'seven']",major product categories,0.9043933153152466,how many major product categories ?,seven,core species
20,"Variable consideration is estimated and recorded at the time that related revenue is recognized. Our estimates reflect the amount by which we expect variable consideration to impact revenue recognized and are generally based on contractual terms or historical experience, adjusted as necessary to reflect our expectations about the future. Our customer payment terms generally range from 45 to 75 days.",45,['Customer payment terms'],zts_RevenuePerformanceObligationDescriptionOfCustomerPaymentTerms,durationItemType,zts,Our customer payment terms generally range from 45 to 75 days.,45 to 75 days,DATE,Our customer payment terms generally range from 45 to 75 days.,['payment terms'],"['customer payment terms', 0.7850919961929321, 'What is 45 to 75 days ?', 'customer payment terms']",customer payment terms,0.7850919961929321,What is 45 to 75 days ?,customer payment terms,Customer payment terms
21,"Variable consideration is estimated and recorded at the time that related revenue is recognized. Our estimates reflect the amount by which we expect variable consideration to impact revenue recognized and are generally based on contractual terms or historical experience, adjusted as necessary to reflect our expectations about the future. Our customer payment terms generally range from 45 to 75 days.",75,['Customer payment terms'],zts_RevenuePerformanceObligationDescriptionOfCustomerPaymentTerms,durationItemType,zts,Our customer payment terms generally range from 45 to 75 days.,45 to 75 days,DATE,Our customer payment terms generally range from 45 to 75 days.,['payment terms'],"['customer payment terms', 0.7850919961929321, 'What is 45 to 75 days ?', 'customer payment terms']",customer payment terms,0.7850919961929321,What is 45 to 75 days ?,customer payment terms,Customer payment terms
22,"Accruals for deductions from revenue are recorded as either a reduction in Accounts receivable or within Accrued expenses, depending on the nature of the contract and method of expected payment. Amounts recorded as a reduction in Accounts receivable as of December 31, 2021 and 2020 are approximately $216 million and $185 million, respectively. As of December 31, 2021, and 2020, accruals for deductions from revenue included in Accrued expenses are approximately $312 million and $226 million, respectively.",216,[],zts_AccrualsforSalesDeductions,monetaryItemType,zts,"Amounts recorded as a reduction in Accounts receivable as of December 31, 2021 and 2020 are approximately $216 million and $185 million, respectively.",approximately $216 million and $185 million,MONEY,"Amounts recorded as a reduction in Accounts receivable as of December 31, 2021 and 2020 are approximately $216 million and $185 million, respectively.",['reduction in Accounts'],"['Amounts recorded as a reduction in Accounts receivable', 0.34475240111351013, 'What is approximately $216 million and $185 million ?', 'Amounts recorded as a reduction in Accounts receivable']",Amounts recorded as a reduction in Accounts receivable,0.3447524011135101,What is approximately $216 million and $185 million ?,Amounts recorded as a reduction in Accounts receivable,Accounts receivable
23,"Accruals for deductions from revenue are recorded as either a reduction in Accounts receivable or within Accrued expenses, depending on the nature of the contract and method of expected payment. Amounts recorded as a reduction in Accounts receivable as of December 31, 2021 and 2020 are approximately $216 million and $185 million, respectively. As of December 31, 2021, and 2020, accruals for deductions from revenue included in Accrued expenses are approximately $312 million and $226 million, respectively.",185,[],zts_AccrualsforSalesDeductions,monetaryItemType,zts,"Amounts recorded as a reduction in Accounts receivable as of December 31, 2021 and 2020 are approximately $216 million and $185 million, respectively.",approximately $216 million and $185 million,MONEY,"Amounts recorded as a reduction in Accounts receivable as of December 31, 2021 and 2020 are approximately $216 million and $185 million, respectively.",['reduction in Accounts'],"['Amounts recorded as a reduction in Accounts receivable', 0.34475240111351013, 'What is approximately $216 million and $185 million ?', 'Amounts recorded as a reduction in Accounts receivable']",Amounts recorded as a reduction in Accounts receivable,0.3447524011135101,What is approximately $216 million and $185 million ?,Amounts recorded as a reduction in Accounts receivable,Accounts receivable
24,"Accruals for deductions from revenue are recorded as either a reduction in Accounts receivable or within Accrued expenses, depending on the nature of the contract and method of expected payment. Amounts recorded as a reduction in Accounts receivable as of December 31, 2021 and 2020 are approximately $216 million and $185 million, respectively. As of December 31, 2021, and 2020, accruals for deductions from revenue included in Accrued expenses are approximately $312 million and $226 million, respectively.",312,[],zts_AccrualsforSalesDeductions,monetaryItemType,zts,"As of December 31, 2021, and 2020, accruals for deductions from revenue included in Accrued expenses are approximately $312 million and $226 million, respectively.",approximately $312 million and $226 million,MONEY,"As of December 31, 2021, and 2020, accruals for deductions from revenue included in Accrued expenses are approximately $312 million and $226 million, respectively.","['accruals for deductions', 'deductions from revenue']","['accruals for deductions from revenue', 0.13967803120613098, 'What is approximately $312 million and $226 million ?', 'accruals for deductions from revenue']",accruals for deductions from revenue,0.1396780312061309,What is approximately $312 million and $226 million ?,accruals for deductions from revenue,accruals for deductions from revenue
25,"Accruals for deductions from revenue are recorded as either a reduction in Accounts receivable or within Accrued expenses, depending on the nature of the contract and method of expected payment. Amounts recorded as a reduction in Accounts receivable as of December 31, 2021 and 2020 are approximately $216 million and $185 million, respectively. As of December 31, 2021, and 2020, accruals for deductions from revenue included in Accrued expenses are approximately $312 million and $226 million, respectively.",226,[],zts_AccrualsforSalesDeductions,monetaryItemType,zts,"As of December 31, 2021, and 2020, accruals for deductions from revenue included in Accrued expenses are approximately $312 million and $226 million, respectively.",approximately $312 million and $226 million,MONEY,"As of December 31, 2021, and 2020, accruals for deductions from revenue included in Accrued expenses are approximately $312 million and $226 million, respectively.","['accruals for deductions', 'deductions from revenue']","['accruals for deductions from revenue', 0.13967803120613098, 'What is approximately $312 million and $226 million ?', 'accruals for deductions from revenue']",accruals for deductions from revenue,0.1396780312061309,What is approximately $312 million and $226 million ?,accruals for deductions from revenue,Accrued expenses
26,"A deferral of revenue may be required in the event that we have not satisfied all customer obligations for which we have been compensated. The transaction price is allocated to the individual performance obligations on the basis of relative stand alone selling price, which is typically based on actual sales prices. Revenue associated with unsatisfied performance obligations are contract liabilities, is recorded within Other current liabilities and Other noncurrent liabilities, and is recognized once control of the underlying products has transferred to the customer. Contract liabilities reflected within Other current liabilities as of December 31, 2020 and subsequently recognized as revenue during 2021 were approximately $6 million. Contract liabilities as of December 31, 2021 were approximately $12 million.",6,['Revenue recognized throughout 2021'],us-gaap_ContractWithCustomerLiabilityRevenueRecognized,monetaryItemType,zts,"Contract liabilities reflected within Other current liabilities as of December 31, 2020 and subsequently recognized as revenue during 2021 were approximately $6 million.",approximately $6 million,MONEY,"Contract liabilities reflected within Other current liabilities as of December 31, 2020 and subsequently recognized as revenue during 2021 were approximately $6 million.","['Contract liabilities', 'Other current liabilities']","['Contract liabilities', 0.6587972640991211, 'What is approximately $6 million ?', 'Contract liabilities']",Contract liabilities,0.6587972640991211,What is approximately $6 million ?,Contract liabilities,Contract liabilities
27,"A deferral of revenue may be required in the event that we have not satisfied all customer obligations for which we have been compensated. The transaction price is allocated to the individual performance obligations on the basis of relative stand alone selling price, which is typically based on actual sales prices. Revenue associated with unsatisfied performance obligations are contract liabilities, is recorded within Other current liabilities and Other noncurrent liabilities, and is recognized once control of the underlying products has transferred to the customer. Contract liabilities reflected within Other current liabilities as of December 31, 2020 and subsequently recognized as revenue during 2021 were approximately $6 million. Contract liabilities as of December 31, 2021 were approximately $12 million.",12,['Contract liabilities'],us-gaap_ContractWithCustomerLiability,monetaryItemType,zts,"Contract liabilities as of December 31, 2021 were approximately $12 million.",approximately $12 million,MONEY,"Contract liabilities as of December 31, 2021 were approximately $12 million.","['Contract liabilities', 'Contract liabilities']","['Contract liabilities', 0.9341017007827759, 'What is approximately $12 million ?', 'Contract liabilities']",Contract liabilities,0.934101700782776,What is approximately $12 million ?,Contract liabilities,Contract liabilities
28,"Advertising expenses relating to production costs are expensed as incurred, and the costs of space in publications are expensed when the related advertising occurs. Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",292,['Advertising and promotion expenses'],us-gaap_AdvertisingExpense,monetaryItemType,zts,"Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",approximately $292 million,MONEY,"Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",[],"['Advertising and promotion expenses', 0.9210307002067566, 'What is approximately $292 million ?', 'Advertising and promotion expenses']",Advertising and promotion expenses,0.9210307002067566,What is approximately $292 million ?,Advertising and promotion expenses,Advertising and promotion expenses
29,"Advertising expenses relating to production costs are expensed as incurred, and the costs of space in publications are expensed when the related advertising occurs. Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",233,['Advertising and promotion expenses'],us-gaap_AdvertisingExpense,monetaryItemType,zts,"Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",$233 million,MONEY,"Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",[],"['', 0, '', '']",,0.0,,,Advertising and promotion expenses
30,"Advertising expenses relating to production costs are expensed as incurred, and the costs of space in publications are expensed when the related advertising occurs. Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",167,['Advertising and promotion expenses'],us-gaap_AdvertisingExpense,monetaryItemType,zts,"Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",$167 million,MONEY,"Advertising and promotion expenses totaled approximately $292 million in 2021, $233 million in 2020 and $167 million in 2019.",[],"['', 0, '', '']",,0.0,,,Advertising and promotion expenses
31,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",80,"['Cost of Sales', 'Cost of sales']",us-gaap_CostOfGoodsAndServicesSold,monetaryItemType,zts,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",approximately $80 million,MONEY,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",[],"['Shipping and handling costs', 0.8527969717979431, 'What is approximately $80 million ?', 'Shipping and handling costs']",Shipping and handling costs,0.8527969717979431,What is approximately $80 million ?,Shipping and handling costs,shipping and handling costs
32,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",66,"['Cost of Sales', 'Cost of sales']",us-gaap_CostOfGoodsAndServicesSold,monetaryItemType,zts,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",$66 million,MONEY,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",[],"['', 0, '', '']",,0.0,,,Shipping and handling costs
33,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",59,"['Cost of Sales', 'Cost of sales']",us-gaap_CostOfGoodsAndServicesSold,monetaryItemType,zts,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",$59 million,MONEY,"Shipping and handling costs totaled approximately $80 million in 2021, $66 million in 2020 and $59 million in 2019.",[],"['', 0, '', '']",,0.0,,,Shipping and handling costs
34,"We capitalize certain costs incurred in connection with obtaining or developing internal use software, including payroll and payroll related costs for employees who are directly associated with the internal use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively. Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",5,['Estimated useful life'],us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,zts,"Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years.",5 to 10 years,DATE,"Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years.","['estimated useful life of years', 'software costs', 'straight line method', 'useful life']","['useful life', 0.9578657746315002, 'what is useful life ?', '5 to 10 years']",useful life,0.9578657746315002,what is useful life ?,5 to 10 years,Capitalized software costs
35,"We capitalize certain costs incurred in connection with obtaining or developing internal use software, including payroll and payroll related costs for employees who are directly associated with the internal use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively. Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",10,['Estimated useful life'],us-gaap_PropertyPlantAndEquipmentUsefulLife,durationItemType,zts,"Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years.",5 to 10 years,DATE,"Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years.","['estimated useful life of years', 'software costs', 'straight line method', 'useful life']","['useful life', 0.9578657746315002, 'what is useful life ?', '5 to 10 years']",useful life,0.9578657746315002,what is useful life ?,5 to 10 years,Capitalized software costs
36,"We capitalize certain costs incurred in connection with obtaining or developing internal use software, including payroll and payroll related costs for employees who are directly associated with the internal use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively. Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",73,['Capitalized internal use software'],us-gaap_CapitalizedComputerSoftwareNet,monetaryItemType,zts,"The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively.",$73 million and,MONEY,"The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively.",['use software'],"['internal use software', 0.8408816456794739, 'What is $73 million and ?', 'internal use software']",internal use software,0.8408816456794739,What is $73 million and ?,internal use software,internal use software
37,"We capitalize certain costs incurred in connection with obtaining or developing internal use software, including payroll and payroll related costs for employees who are directly associated with the internal use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively. Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",59,['Capitalized internal use software'],us-gaap_CapitalizedComputerSoftwareNet,monetaryItemType,zts,"The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively.",$59 million,MONEY,"The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively.",['use software'],"['internal use software', 0.9837909936904907, 'What is $59 million ?', 'internal use software']",internal use software,0.9837909936904908,What is $59 million ?,internal use software,Internal use software
38,"We capitalize certain costs incurred in connection with obtaining or developing internal use software, including payroll and payroll related costs for employees who are directly associated with the internal use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively. Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",52,['Depreciation expense'],us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,zts,"Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",$52 million,MONEY,"Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in","['Depreciation expense for capitalized software', 'Depreciation expense']","['Depreciation expense for capitalized software', 0.7193119525909424, 'what is Depreciation expense for capitalized software ?', '$52 million']",Depreciation expense for capitalized software,0.7193119525909424,what is Depreciation expense for capitalized software ?,$52 million,Depreciation expense for capitalized software
39,"We capitalize certain costs incurred in connection with obtaining or developing internal use software, including payroll and payroll related costs for employees who are directly associated with the internal use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively. Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",46,['Depreciation expense'],us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,zts,"Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",$46 million,MONEY,"Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in","['Depreciation expense for capitalized software', 'Depreciation expense']","['', 0, '', '']",,0.0,,,Depreciation expense for capitalized software
40,"We capitalize certain costs incurred in connection with obtaining or developing internal use software, including payroll and payroll related costs for employees who are directly associated with the internal use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in Property, plant and equipment and are amortized using the straight line method over the estimated useful life of 5 to 10 years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The company capitalized $73 million and $59 million of internal use software for the years ended December 31, 2021 and 2020, respectively. Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",27,['Depreciation expense'],us-gaap_CapitalizedComputerSoftwareAmortization1,monetaryItemType,zts,"Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in",$27 million,MONEY,"Depreciation expense for capitalized software was $52 million in 2021, $46 million in 2020 and $27 million in","['Depreciation expense for capitalized software', 'Depreciation expense']","['', 0, '', '']",,0.0,,,Depreciation expense for capitalized software
41,"The recorded amounts of accounts receivable approximate fair value because of their relatively short term nature. As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.","1,133","['Accounts receivable, less allowance for doubtful accounts of $17 in 2021 and $20 in 2020', 'Accounts receivable, less allowance for doubtful accounts']",us-gaap_AccountsReceivableNetCurrent,monetaryItemType,zts,"As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.","$1,133 million and $1,013 million",MONEY,"As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.","['receivable less allowance', 'receivable less allowance for doubtful accounts', 'receivable less allowance', 'other receivables as trade notes', 'receivable less allowance', 'doubtful accounts', 'other receivables', 'trade notes']","['Accounts receivable', 0.9661213159561157, 'What is $1,133 million and $1,013 million ?', 'Accounts receivable']",Accounts receivable,0.9661213159561156,"What is $1,133 million and $1,013 million ?",Accounts receivable,"Accounts receivable, less allowance for doubtful accounts"
42,"The recorded amounts of accounts receivable approximate fair value because of their relatively short term nature. As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.","1,013","['Accounts receivable, less allowance for doubtful accounts of $17 in 2021 and $20 in 2020', 'Accounts receivable, less allowance for doubtful accounts']",us-gaap_AccountsReceivableNetCurrent,monetaryItemType,zts,"As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.","$1,133 million and $1,013 million",MONEY,"As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.","['receivable less allowance', 'receivable less allowance for doubtful accounts', 'receivable less allowance', 'other receivables as trade notes', 'receivable less allowance', 'doubtful accounts', 'other receivables', 'trade notes']","['Accounts receivable', 0.9661213159561157, 'What is $1,133 million and $1,013 million ?', 'Accounts receivable']",Accounts receivable,0.9661213159561156,"What is $1,133 million and $1,013 million ?",Accounts receivable,"Accounts receivable, less allowance for doubtful accounts"
43,"The recorded amounts of accounts receivable approximate fair value because of their relatively short term nature. As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.",47,['Other receivables'],us-gaap_OtherReceivablesNetCurrent,monetaryItemType,zts,"As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.",approximately $47 million and $48 million,MONEY,"As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.","['receivable less allowance', 'receivable less allowance for doubtful accounts', 'receivable less allowance', 'other receivables as trade notes', 'receivable less allowance', 'doubtful accounts', 'other receivables', 'trade notes']","['Accounts receivable', 0.3707001209259033, 'What is approximately $47 million and $48 million ?', 'Accounts receivable']",Accounts receivable,0.3707001209259033,What is approximately $47 million and $48 million ?,Accounts receivable,"Accounts receivable, less allowance for doubtful accounts"
44,"The recorded amounts of accounts receivable approximate fair value because of their relatively short term nature. As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.",48,['Other receivables'],us-gaap_OtherReceivablesNetCurrent,monetaryItemType,zts,"As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.",approximately $47 million and $48 million,MONEY,"As of December 31, 2021 and 2020, Accounts receivable, less allowance for doubtful accounts, of $1,133 million and $1,013 million, respectively, includes approximately $47 million and $48 million, respectively, of other receivables, such as trade notes receivable and royalty receivables, among others.","['receivable less allowance', 'receivable less allowance for doubtful accounts', 'receivable less allowance', 'other receivables as trade notes', 'receivable less allowance', 'doubtful accounts', 'other receivables', 'trade notes']","['Accounts receivable', 0.3707001209259033, 'What is approximately $47 million and $48 million ?', 'Accounts receivable']",Accounts receivable,0.3707001209259033,What is approximately $47 million and $48 million ?,Accounts receivable,"Accounts receivable, less allowance for doubtful accounts"
45,"We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information. Under the benefit recognition model, if the initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to more likely than not; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re evaluate our tax positions based on the results of audits of federal, state and foreign income tax filings, statute of limitations expirations, changes in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the ""more likely than not"" standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in Provision for taxes on income and are classified on our Consolidated Balance Sheets with the related tax liability.",50,['Percentage of being realized upon settlement'],zts_IncomeTaxContingencyBenefitRecognitionModelPercent,percentItemType,zts,"We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.",greater than 50%,PERCENT,"We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.","['full knowledge of relevant information', 'tax position', 'appropriate authority', 'full knowledge', 'relevant information']","['likely of being realized upon settlement', 0.17227403819561005, 'What is greater than 50% ?', 'likely of being realized upon settlement']",likely of being realized upon settlement,0.17227403819561,What is greater than 50% ?,likely of being realized upon settlement,being realized upon settlement
46,"As of December 31, 2021 and 2020, accruals for asset retirement obligations are $25 million and are primarily included in Other noncurrent liabilities.",25,"['Accruals for asset retirement obligations, non current']",us-gaap_AssetRetirementObligationsNoncurrent,monetaryItemType,zts,"As of December 31, 2021 and 2020, accruals for asset retirement obligations are $25 million and are primarily included in Other noncurrent liabilities.",$25 million,MONEY,"As of December 31, 2021 and 2020, accruals for asset retirement obligations are $25 million and are primarily included in Other noncurrent liabilities.","['accruals for asset retirement obligations', 'asset retirement obligations', 'Other noncurrent liabilities']","['accruals for asset retirement obligations', 0.9941987991333008, 'what is accruals for asset retirement obligations ?', '$25 million']",accruals for asset retirement obligations,0.9941987991333008,what is accruals for asset retirement obligations ?,$25 million,Asset retirement obligations
47,"Over the course of our history, we have focused on developing a diverse portfolio of animal health products, including medicines, vaccines and diagnostics, complemented by biodevices, genetic tests and a range of services. We refer to all different brands of a particular product, or its dosage forms for all species, as a product line. We have approximately 300 comprehensive product lines, including products for both companion animals and livestock within each of our major product categories.",300,['Number of Comprehensive Product Lines'],zts_NumberofComprehensiveProductLines,integerItemType,zts,"We have approximately 300 comprehensive product lines, including products for both companion animals and livestock within each of our major product categories.",approximately 300,CARDINAL,"We have approximately 300 comprehensive product lines, including products for both companion animals and livestock within each of our major product categories.","['products for companion animals', 'products', 'comprehensive product lines', 'companion animals', 'major product categories']","['comprehensive product lines', 0.8676983118057251, 'What is approximately 300 ?', 'comprehensive product lines']",comprehensive product lines,0.8676983118057251,What is approximately 300 ?,comprehensive product lines,comprehensive product lines
48,Revenue exceeded $100 million in twelve countries outside the U.S. in 2021 and eleven countries outside the U.S. in 2020 and 2019. The U.S. was the only country to contribute more than 10% of total revenue in each year.,100,"['Revenue by country, exceeded']",zts_RevenueByCountryExceeded,monetaryItemType,zts,Revenue exceeded $100 million in twelve countries outside the U.S. in 2021 and eleven countries outside the U.S. in 2020 and 2019.,$100 million,MONEY,Revenue exceeded $100 million in twelve countries outside the U.S. in 2021 and eleven countries outside the U.S. in 2020 and 2019.,"['countries outside U.S.', 'countries outside U.S.']","['Revenue', 0.9701617360115051, 'What is $100 million ?', 'Revenue']",Revenue,0.9701617360115052,What is $100 million ?,Revenue,Revenue outside the U.S.
49,Revenue exceeded $100 million in twelve countries outside the U.S. in 2021 and eleven countries outside the U.S. in 2020 and 2019. The U.S. was the only country to contribute more than 10% of total revenue in each year.,100,"['Revenue by country, exceeded']",zts_RevenueByCountryExceeded,monetaryItemType,zts,Revenue exceeded $100 million in twelve countries outside the U.S. in 2021 and eleven countries outside the U.S. in 2020 and 2019.,$100 million,MONEY,Revenue exceeded $100 million in twelve countries outside the U.S. in 2021 and eleven countries outside the U.S. in 2020 and 2019.,"['countries outside U.S.', 'countries outside U.S.']","['Revenue', 0.9701617360115051, 'What is $100 million ?', 'Revenue']",Revenue,0.9701617360115052,What is $100 million ?,Revenue,Revenue in twelve countries
